Navigation Links
Phase 2a Multi-Dose Study Initiated by MedImmune in Patients With Asthma to Further Expand Anti-Interleukin-9 Program
Date:8/19/2007

or otherwise; Genaera's reliance on its collaborators, in connection with the development and commercialization of Genaera's product candidates; market acceptance of Genaera's products, if regulatory approval is achieved; competition; general financial, economic, regulatory and political conditions affecting the biotechnology and pharmaceutical industry; and the other risks and uncertainties discussed in this announcement and in Genaera's filings with the U.S. Securities and Exchange Commission, all of which are available from the Commission in its EDGAR database at http://www.sec.gov as well as other sources. You are encouraged to read these reports. Given the uncertainties affecting development stage pharmaceutical companies, you are cautioned not to place undue reliance on any such forward-looking statements, any of which may turn out to be wrong due to inaccurate assumptions, unknown risks, uncertainties or other factors. Genaera does not intend (and it is not obligated) to publicly update, revise or correct these forward-looking statements or the risk factors that may relate thereto.

Contact:

Genaera Corporation Susan Neath - Porter Novelli Life Sciences

Investor Relations Media

(610) 941-5675 (619) 849-6007

http://www.genaera.com sneath@pnlifesciences.com


'/>"/>
SOURCE Genaera Corporation

Copyright©2007 PR Newswire.

Page: 1 2 3 4

Related medicine technology :

1. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
2. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
3. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
4. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
5. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
6. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
7. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
8. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
9. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
10. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
11. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2015)... 2015 ... kongestive Herzinsuffizienz (CHF) in seiner ersten klinischen ...   Die israelische Firma ... für Patienten mit kongestiver Herzinsuffizienz (CHF) entwickelt ... Finanzierungsvorhaben über 5 Mio. USD abgeschlossen hat. ...
(Date:2/27/2015)... , Feb. 27, 2015  Two ... increasing in applications as their effectiveness is ... Kalorama Information.  Kalorama Information says that while ... the most powerful tool in proteomic biomarker ... MS) through its traditional techniques has struggled ...
(Date:2/26/2015)... NORTH CHICAGO, Ill. , Feb. 26, 2015 ... announced that 15 abstracts of studies in its ... for presentation during the 67 th American ... Washington, D.C. , from April 18-25. The ... FDA-approved product, DUOPA, in addition to investigational treatments ...
Breaking Medicine Technology:Vectorious Medical Technologies schließt Finanzierungsvorhaben über 5 Mio. USD ab 2Report: "Softer" Mass Spec Techniques Gaining Popularity in Biomarker Discovery 2Report: "Softer" Mass Spec Techniques Gaining Popularity in Biomarker Discovery 3AbbVie's Ongoing Research in Neuroscience and Oncology will be Featured at the 2015 American Academy of Neurology Annual Meeting 2AbbVie's Ongoing Research in Neuroscience and Oncology will be Featured at the 2015 American Academy of Neurology Annual Meeting 3AbbVie's Ongoing Research in Neuroscience and Oncology will be Featured at the 2015 American Academy of Neurology Annual Meeting 4AbbVie's Ongoing Research in Neuroscience and Oncology will be Featured at the 2015 American Academy of Neurology Annual Meeting 5AbbVie's Ongoing Research in Neuroscience and Oncology will be Featured at the 2015 American Academy of Neurology Annual Meeting 6AbbVie's Ongoing Research in Neuroscience and Oncology will be Featured at the 2015 American Academy of Neurology Annual Meeting 7
... American Pharmacists Association (APhA) is encouraging consumers to get ... as the site to receive their vaccine. Pharmacists in ... authorized to administer influenza vaccines and, as of June ... trained to administer immunizations. "The pharmacist is ...
... Exceptionally high costs.  Long research and development cycles.  Low ...  Dependence on out-dated information technology options.  It,s not just ... information being wasted.   Such ... have led to the formation of a new company, ...
Cached Medicine Technology:Consumers Encouraged to Get Immunized Against Influenza 2RedOak Logic's Mission: Transform Pharmaceutical Industry Drug Development 2RedOak Logic's Mission: Transform Pharmaceutical Industry Drug Development 3RedOak Logic's Mission: Transform Pharmaceutical Industry Drug Development 4
(Date:3/1/2015)... 01, 2015 A federal court ... ) scheduled to go to trial in October ... witness to provide testimony regarding the role an ... the Profemur device, Bernstein Liebhard LLP comments. According ... Northern District of Iowa on February 25th, Wright ...
(Date:3/1/2015)... 01, 2015 “ The Barrel Mill ” ... Report, which takes a look at the latest and coolest ... host of NewsWatch and a technology expert, conducted the review ... flavor to drinks. , According to Home Distillation of Alcohol, ... spirits. Well, there’s a pretty cool product that’ll help anyone ...
(Date:2/28/2015)... Heart diseases are on the rise ... urban adult population and 5 percent of rural adult ... 20-30 percent of them require specialized investigation and treatment ... vascular diseases (CVD). , A division of Indian Business ... report titled “Indian Coronary Stent Market Forecast to 2019”. ...
(Date:2/28/2015)... February 28, 2015 The Classic ... offering a new special. Throughout all of March ... , This service can help overall ... and pain. Patients may notice certain symptoms that suggest ... These symptoms include: , 1.    Pain, clicking, and popping ...
(Date:2/28/2015)... A study out of the University of ... for the treatment of a hereditary ocular condition that ... by Dr. Robert MacLaren, professor of ophthalmology at the ... Journal on January 16, 2014 , the study treated ... that mostly affects men and leads to the degeneration ...
Breaking Medicine News(10 mins):Health News:Wright Profemur Hip Lawyers at Bernstein Liebhard LLP Comment on Court’s Decision Regarding Testimony Pertaining to Prototype for Profemur Hip Replacement 2Health News:Wright Profemur Hip Lawyers at Bernstein Liebhard LLP Comment on Court’s Decision Regarding Testimony Pertaining to Prototype for Profemur Hip Replacement 3Health News:An Oak Infusion Spiral was Featured on NewsWatch Television on January 30, 2015 2Health News:India Coronary Stent Market 2019 Forecasts Analysis in New Research Report Available at MarketReportsOnline.com 2Health News:India Coronary Stent Market 2019 Forecasts Analysis in New Research Report Available at MarketReportsOnline.com 3Health News:Classic Denture Center in Portland Oregon is Offering March Discount 2Health News:New Gene Therapy Procedure Could Hold Key to Preventing Blindness for Certain Patients 2
... only a few basic ways to fight viruses. A vaccine can ... invade the body//. If a virus manages to establish itself, a ... its spread. And if all else fails, a doctor may quarantine ... scientists are exploring a fundamentally different strategy to fight viruses. They ...
... Trusts have welcomed a move to bring an end to the ... ,Till now, when a health trust falls into deficit, ... debts but in addition, some money is cut off from its ... this has meant that some health trusts find it virtually impossible ...
... provide detailed information on how well a transplanted heart ... as the Allomap test, is currently used to detect ... invasive heart muscle biopsies, but has now been shown ... the heart before pumping, and the electrical properties of ...
... the popular anti-clotting drug clopidogrel (Plavix) when taken along with ... adverse bleeding event.// ,The study, to be ... Session on March 27 at 9 am (abstract 1027-18), found ... worsen bleeding after off-pump heart bypass surgery. ...
... children, yet the number of pediatric orthopedists trained to ... decreasing nationwide. The management of fractures in children is ... is needed to provide the best care for these ... for Special Surgery (HSS). ,Fractures in ...
... of Indian MPs has come together to launch a fight ... start a massive awareness drive and also seeking a special ... that at least two people die of the infectious disease ... have decided to form a group next month and to ...
Cached Medicine News:Health News:Scientists Explore Ways to Lure Viruses to Their Death 2Health News:Scientists Explore Ways to Lure Viruses to Their Death 3Health News:Double-penalty System for Bankrupt Health Trusts Lifted 2Health News:Gene Test Shown to Measure Heart Function After Transplant 2Health News:Plavix Safe During and After Heart Bypass 2Health News:Number of Specialists Best at Treating Children's Fractures Decreasing 2Health News:Number of Specialists Best at Treating Children's Fractures Decreasing 3Health News:Indian Parliamentarians Join to Fight Against TB 2
... Tri-Active is the result of DEKA ... combination of three different methods capable ... your skin. This treatment is designed ... cellulite through the combined action of ...
... Smartepil II Plus is the latest evolution ... fast, safe and reliable system for epilation ... preset protocols in its modern software, Smartepil ... vascular treatments in full respect of the ...
This instrument measures intraocular pressure without,contacting. Alignment is performed semi-automatically....
The convenience of safe and precise Patient Controlled Analgesia in a flexible system designed with advanced technology. This is progressive, innovative, and effective pain management in a sophistica...
Medicine Products: